DEA Detects New 'Orphine' Synthetic Opioid in Knoxville: What Families Need to Know

The Drug Enforcement Administration (DEA) has identified a concerning new substance in the illicit drug supply—a synthetic opioid compound never before seen in national forensic data. The discovery, made in Knoxville, Tennessee, marks the first appearance of a compound called 5-chloro desmethyl chlorphine, part of a class of substances known as "orphines."

This detection underscores a troubling trend: as law enforcement and public health agencies work to control known threats like fentanyl, illicit manufacturers continue to develop new chemical compounds that evade detection and regulation—often with even greater potency and risk.

What Are Orphines?

Orphines represent a class of synthetic opioids first developed in the 1960s as potential pain medications. Pharmaceutical researchers abandoned them due to severe safety concerns, including profound respiratory depression and high potential for abuse. Despite being shelved decades ago, these compounds have now emerged in the illegal drug market.

Pharmacologically, orphines act as powerful agonists at the μ-opioid receptor—the same receptor targeted by fentanyl, heroin, and prescription opioids like oxycodone. However, preliminary toxicological analyses suggest that some orphine analogs may be multiple times more potent than fentanyl, which is already 50-100 times stronger than morphine.

The Knoxville seizure contained material that was 34% pure—a significant concentration for such a potent substance. The DEA confirmed this was the first time this specific compound has appeared in the National Forensic Laboratory Information System (NFLIS), which tracks drug evidence from law enforcement agencies nationwide.

The Evolving Drug Threat

The emergence of orphines fits a broader pattern that federal officials have been tracking. In a public safety advisory issued May 12, 2026, the DEA warned that the United States faces an "unprecedented and evolving drug threat" as fentanyl becomes increasingly mixed with a growing array of synthetic substances.

The advisory highlighted several dangerous trends:

• Fentanyl-adulterant cocktails: Drug trafficking organizations are mixing fentanyl with non-opioid sedatives like xylazine and medetomidine (veterinary tranquilizers), as well as ultra-potent synthetic opioids including nitazenes and cychlorphine.

• Counterfeit pills: Illicit manufacturers press these mixtures into pills designed to mimic legitimate prescription medications like oxycodone or Xanax. Users often have no way to distinguish real from counterfeit.

• Rapid chemical innovation: As specific substances become controlled or detected, manufacturers pivot to new chemical structures that may evade standard testing and legal restrictions.

"The drug market is evolving," said Jonathan Pullen, associate chief of operations for the DEA's South Central Region. "As we pressure one substance, they pivot to another. There's always something new, and it's usually more dangerous."

Clinical Implications and Overdose Risk

The medical implications of orphines and similar ultra-potent synthetic opioids are significant for both users and healthcare providers.

Rapid-onset respiratory depression: Due to their extreme potency, these substances can cause life-threatening respiratory depression within minutes of exposure. The window for intervention may be shorter than with traditional opioids.

Naloxone challenges: While naloxone (Narcan) remains effective at reversing opioid overdoses, ultra-potent synthetics may require higher or repeated doses. Some adulterants like xylazine and medetomidine are not opioids at all—meaning naloxone cannot reverse their sedative effects, even though it will still address the opioid component of an overdose.

Detection difficulties: Standard toxicology screens may not detect orphines and other novel synthetic opioids. This creates challenges for emergency departments trying to identify what substance caused an overdose, and for medical examiners determining cause of death.

Unpredictable dosing: Illicit drug manufacturing lacks quality control. A user who survives one batch may overdose on another containing higher concentrations or different substances entirely.

What This Means for Families and Communities

For families concerned about a loved one's substance use, the emergence of orphines reinforces several critical safety principles:

Assume unpredictability

Any illicit drug obtained outside a pharmacy may contain fentanyl or similar potent synthetics. This includes substances that appear to be prescription pills, cocaine, methamphetamine, or heroin. There is no visual way to identify contaminated drugs.

Carry naloxone—and know how to use it

Naloxone remains the most important tool for reversing opioid overdoses. Family members, friends, and anyone in contact with people who use drugs should:

• Keep naloxone readily accessible
• Learn the signs of overdose (slow or stopped breathing, blue lips or fingernails, unresponsiveness)
• Administer naloxone immediately if overdose is suspected—don't wait for emergency responders
• Be prepared to give multiple doses if the person doesn't respond within 2-3 minutes
• Call 911 regardless of naloxone response

Naloxone is available without prescription in most states and is often provided free through harm reduction programs, health departments, and some pharmacies.

Recognize that "one pill can kill"

The DEA emphasizes that counterfeit pills are driving many overdose deaths among people who may not consider themselves "drug users." A teenager who takes a pill obtained from a friend—believing it to be a legitimate prescription medication—may be consuming a lethal dose of fentanyl or an even more potent synthetic.

Don't use alone

If someone is going to use substances, using in the presence of others who can recognize overdose signs and administer naloxone significantly improves survival odds. Never Use Alone (neverusealone.com) and similar services provide phone-based monitoring for people using alone.

Seek treatment

The most effective way to eliminate overdose risk is to stop using illicit substances. Medication-assisted treatment (MAT) with buprenorphine or methadone, combined with counseling and support services, has strong evidence for helping people achieve and maintain recovery from opioid use disorder.

Where to Get Help

If you or someone you love is struggling with substance use, resources are available:

• SAMHSA National Helpline: 1-800-662-HELP (4357) — Free, confidential, 24/7 treatment referral and information
• Crisis Text Line: Text HOME to 741741 to connect with a crisis counselor
• FindTreatment.gov: Searchable database of treatment facilities nationwide
• Never Use Alone: 1-877-696-1996 — Phone-based overdose prevention for people using alone

For naloxone access, contact your local health department, harm reduction organization, or pharmacy. Many jurisdictions have standing orders allowing pharmacists to dispense naloxone without an individual prescription.

Looking Ahead

The detection of orphines in Knoxville serves as a reminder that the illicit drug supply continues to evolve in dangerous directions. Federal agencies, public health departments, and harm reduction organizations are working to track these emerging threats and adapt response strategies accordingly.

For individuals and families, the core message remains consistent: the only safe assumption is that any illicit substance may contain deadly potent synthetics. Naloxone access, overdose recognition skills, and pathways to treatment remain the most important protective measures against this evolving threat.

This alert was medically reviewed by Dr. Rachel Bennett, MD, a board-certified addiction medicine physician. Last reviewed: June 6, 2026.